Surgery-free breast cancer treatment tested in new trial

NCT ID NCT07245316

Not yet recruiting Disease control Sponsor: Jeong Eon Lee Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether people with certain non-invasive or early breast conditions (like ductal carcinoma in situ) can safely skip surgery and instead take hormone-blocking medication. The goal is to see if this approach keeps cancer from coming back over five years. The trial will enroll 340 women whose biopsy shows hormone-sensitive, HER2-negative disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: endocrine therapy (hormone-blocking medication)
What this could lead to: If successful, this could offer a way to manage certain early breast conditions with medication alone, avoiding the need for surgery.
What could go wrong: This is an early-stage study without a control group, so results may not confirm that skipping surgery is safe. There is a risk that cancer could return or progress without surgical removal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL DUCTAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast intraductal proliferative lesion ductal breast carcinoma in situ lobular breast carcinoma in situ invasive breast carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCTAL CARCINOMA IN SITU OF THE BREAST

Contacts and locations

Locations

Samsung Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.